Indian Journal of Dermatology
  Publication of IADVL, WB
  Official organ of AADV
Indexed with Science Citation Index (E) , Web of Science and PubMed
 
Users online: 1552  
Home About  Editorial Board  Current Issue Archives Online Early Coming Soon Guidelines Subscriptions  e-Alerts    Login  
    Small font sizeDefault font sizeIncrease font size Print this page Email this page


 
Table of Contents 
CASE REPORT
Year : 2013  |  Volume : 58  |  Issue : 2  |  Page : 142-144
Multifocal fixed drug eruption with COX-2 inhibitor-celecoxib


1 Department of Dermatology, Maulana Azad Medical College and Associated Lok Nayak Hospital, New Delhi, India
2 Department of Pathology, National Institute of Pathology, ICMR, Safdarjang, New Delhi, India
3 Department of Dermatology, Jawaharlal Institute of Medical Science, Porampat, Manipur, India

Date of Web Publication5-Mar-2013

Correspondence Address:
Rashmi Sarkar
Department of Dermatology, Maulana Azad Medical College and Associated Lok Nayak Hospital, New Delhi
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0019-5154.108057

Rights and Permissions

   Abstract 

Cyclooxygenase-2 (COX-2) inhibitors are rapidly becoming the first choice nonsteroidal anti-inflammatory drugs (NSAIDs) for various rheumatological and other painful conditions. However, they might not be as safe or free of side effects as they are considered to be. These COX-2inhibitors may cause a variety of dermatological and systemic side effects of which we should be aware to avoid their indiscriminate use. We hereby report a case of multifocal fixed drug eruption (FDE) with celecoxib which has not yet been reported in Indian settings.


Keywords: Celecoxib, COX-2 inhibitors, drug reaction, multifocal fixed drug eruption


How to cite this article:
Chugh S, Sarkar R, Garg VK, Singh A, Keisham C. Multifocal fixed drug eruption with COX-2 inhibitor-celecoxib. Indian J Dermatol 2013;58:142-4

How to cite this URL:
Chugh S, Sarkar R, Garg VK, Singh A, Keisham C. Multifocal fixed drug eruption with COX-2 inhibitor-celecoxib. Indian J Dermatol [serial online] 2013 [cited 2019 Sep 16];58:142-4. Available from: http://www.e-ijd.org/text.asp?2013/58/2/142/108057

What was known? The COX 2 inhibitors like celecoxib are rather indiscriminately prescribed in specialities like orthopedics for the management of acute and chronic painful conditions. It has a sulphonamide moiety which is known to cause cross reactivity in patients allergic tosulfonamides. However, multifocal fixed drug eruption (FDE) with celecoxib has been rarely reported in the literature.



   Introduction Top


Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most widely used medications-both by prescription and over the counter. The cyclooxygenase-2 (COX-2) inhibitors, for example, celecoxib, are becoming the drugs of choice for the treatment of various surgical and orthopedic conditions. These compounds decrease the production of prostaglandin through the inhibition of COX-2 while sparing cyclooxygenase-1 (COX-1), and thereby cause significantly fewer serious gastrointestinal adverse events such as ulceration and bleeding than the nonselective NSAIDs. They are being prescribed indiscriminately and are considered relatively free of all side effects even in patients sensitive to classical NSAIDs. [1],[2] However, reports of their safety, both cutaneous and systemic, are rather conflicting. [3],[4],[5] Most of the known adverse cutaneous reactions to COX-2 inhibitors have been attributed to either celecoxib or rofecoxib. They include urticaria/angioedema (by far the most common), Sweet's syndrome, vasculitis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN), and maculopapular rash. Though numerous adverse effects of celecoxib have been reported [Table 1], to our knowledge there is only one case of FDE and only a single case of multifocal FDE with celecoxib reported in the literature. [6],[7] A second case of multifocal drug reaction from celecoxib is hereby being reported.
Table 1: All reported cutaneous drug eruptions to celecoxib till date


Click here to view



   Case Report Top


A 28-year-old nonatopic man presented with multiple (12), round, well-circumscribed erythematous-to-reddish brown patches of sizes ranging from 2 × 3 cm to 10 × 12 cm in diameter. The lesions were scattered asymmetrically over the trunk and upper and lower limbs [Figure 1]. A few of the lesions had central necrosis and blistering with hemorrhagic fluid. The lesions were associated with mild pruritus and burning sensation. The patient had no fever or other constitutional symptoms. There was no mucosal involvement and Nikolsky's sign was negative. No systemic abnormalities were found on physical and routine laboratory examination. The lesions appeared two hours after theinitialingestion of 200 mg of celecoxib which was prescribed to the patient for joint pains. The patient had not taken any other drug in the past one month. However, he had previously taken NSAIDs (not COX-2 inhibitors) and sulfa drugs on several occasions without any adverse effects. A clinical diagnosis of multifocal FDE was suspected based on clinical findings and the temporal association of drug intake. Histopathologically, the lesions showed features consistent with FDE [Figure 2]. Celecoxib was thereby discontinued, and the patient was treated with antihistaminics, topical steroids, and a short course of oral steroids tapered rapidly over three weeks. After three weeks, all the lesions subsided, leaving brownish black hyperpigmentation. One month after the resolution of the eruption, oral provocation was undertaken and the patient was given 50 mg of celecoxib (1/4 th of the therapeutic dose) orally. Reactivation of the lesions occurred within 24 hours which subsided with topical steroids after two weeks with residual postinflammatory hyperpigmentation.
Figure 1: Photograph showing multiple well defined erythematous to hyperpigmented plaques present over the back of the patient

Click here to view
Figure 2: Photomicrograph showing hyperkeratosis, focal interface degeneration with lichenoid inflammatory infiltrate and melanin incontinence (HE, ×100)

Click here to view



   Discussion Top


FDEs, responsible for around 10% of all adverse drug reactions, occur frequently with NSAIDs. It characteristically presents as a round, sharply circumscribed, edematous patch with violaceous or dusky erythema associated with pruritus or burning. [2] Vesicles or bullae may develop and the lesions heal with residual hyperpigmentation. The diagnostic gold standard is drug rechallenge by oral provocation leading to recurrence of lesions at the same site or multiple newer sites. Multifocal FDE is a rare cutaneous disorder characterized by numerous erythematous to violaceous well-demarcated plaques occurring on multiple sites each time the causative or a chemically related drug is taken. Celecoxib, a selective COX-2 inhibitor, is a diaryl-substituted pyrazole derivative containing a sulphonamide substituent. Because of this structural component, celecoxib is contraindicated for use in patients who have demonstrated allergic reactions to sulfonamides. NSAIDs and COX-2 inhibitors with a sulphonamide structure could possibly cross-react with sulfonamides. [8] The sulfonamide-type reactions (erythema multiforme, Stevens-Johnson syndrome, TEN, and maculopapular rash) were found to be twice as common with celecoxib than with other COX-2 inhibitors without the sulfonamide structure. The pathogenesis of these drug reactions is T cell-mediated type IV hypersensitivity reaction. However, conflicting information exists in the literature regarding cross-reactivity among the various sulfonamide-containing medications based on biochemical data including chemistry, metabolism, immune responses, and clinical cases. [9] The major difference between sulphonamide antimicrobials and celecoxib is the presence of an aromatic amine group at the N4 position and a substituted ring at the N1 position in antimicrobials, whereas celecoxib is a nonaromatic amine lacking them. In susceptible individuals, the hydroxylamine metabolite (from the aromatic ring) and the N1 substituent lead to cytotoxic and immunological events that eventually result in adverse reactions including type I and IV hypersensitivity reactions and severe skin reactions such as TEN. Hence, these skin reactions are uncommon with celecoxib. Similarly, there is controversial data on cross-reactivity or safety of COX-2 inhibitors in patients sensitive to classic NSAIDS. Sanchez-Borges et al., in their review of cutaneous reactions to selective COX-2 inhibitors, reported that among patients previously exhibiting urticaria or angioedema triggered by classic NSAIDs, only 1.6% developed urticaria or angioedema to rofecoxib and 11.2% to celecoxib. [1] Similarly, cross-reactions toCOX-2inhibitors in patients sensitive to classical NSAIDs have been reported, but in our case, the patient had tolerated NSAIDs well on previous occasions. These COX-2 inhibitors are costlier and donot have better safety profilesthan conventional NSAIDs. [10] Rofecoxib has already been banned in view of its systemic side effects. As they are rapidly becoming the first choice of NSAIDs, the purpose of this case report is to make physicians aware ofthepossibility of these infrequent side effects and be cautious of the unwarranted use of COX-2 inhibitors.

 
   References Top

1.Sanches Borges M, Capriles-Hutlett A, Caballero-Fonseca F, Perez CR. Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions. Ann Allergy Asthma Immunol 2001;87:201-4.  Back to cited text no. 1
    
2.Cimbollek S, Quiralte J, Avila R. COX-2 Inhibitors in patients with sensitivity to nonselective NSAIDs. N Engl J Med 2009;361:2197-8.  Back to cited text no. 2
    
3.Sarkar R, Kaur C, Kanwar AJ. Erythema multiforme due to rofecoxib. Dermatology 2002;204:304-5.  Back to cited text no. 3
    
4.Are rofecoxib and celecoxib safer NSAIDs? Drug Ther Bull 2000;38:81-6.  Back to cited text no. 4
    
5.Liccardi G, Salzillo A, Piccolo A, Senna G, Piscitelli E, D' Amato M, et al. Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs. Eur Ann Allergy Clin Immunol 2005;37:50-3.  Back to cited text no. 5
    
6.Bandyopadhyay D. Celecoxib induced fixed drug eruption. Clin Exp Dermatol 2003;28:452.  Back to cited text no. 6
    
7.Bellini V, Stingeni L, Lisi P. Multifocal fixed drug eruption due to celecoxib. Dermatitis 2009;20:174-6.  Back to cited text no. 7
    
8.Kaur C, Sarkar R, Kanwar AJ. Fixed drug eruption to Rofecoxib with cross reactivity to sulfonamides. Dermatology 2001;203:351.  Back to cited text no. 8
    
9.Knowles S, Shapiro L, Shear NH. Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Revisiting the meaning of 'sulfa' allergy. Drug Saf 2001;24:239-47.  Back to cited text no. 9
    
10.Evensen S, Spigset O, Slordal L. COX-2 inhibitors--one step forward and two steps back. Tidsskr Nor Laegeforen 2005;125:875-8.  Back to cited text no. 10
    

What is new? We report this case to highlight that a severe drug reaction like a multifocal fixed drug reaction can also occur with celecoxib; hence, caution should be exercised while prescribing them in clinical practice. We also review the literature for various cutaneous drug reactions reported for celecoxib till date.


    Figures

  [Figure 1], [Figure 2]
 
 
    Tables

  [Table 1]



 

Top
Print this article  Email this article
 
 
  Search
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Article in PDF (1,175 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


    Abstract
   Introduction
   Case Report
   Discussion
    References
    Article Figures
    Article Tables

 Article Access Statistics
    Viewed2099    
    Printed43    
    Emailed0    
    PDF Downloaded67    
    Comments [Add]    

Recommend this journal